price close busi april
domin global leader next
gener sequenc instrument
biomed devic servic
growth back-end load fine-tun
estim ahead call buy
continu like one top pick despit fact
expect growth back-end load year think setup
favor believ consensu revenu earn estim
reason remain hub number precis medicin spoke
expect anoth good year reiter buy rate pt ahead
compani report expect come thursday close
preview primarili shift revenu ep lower
street-high estim move line consensu lower revenue
estim y/i prior vs street
guid q/q less lower
adj ep estim y/i prior vs street
model novaseq placement consum rev
y/i q/q assum y/i q/q seq consum
lower forecast services/oth rev y/i given
uncertainti dtc genom revenu time year model seq instrument
rev y/i q/q line ilmn guid
call
updat guid rev y/i adj ep
flat slightli y/i novaseq shipment expect updat
guid consensu look rev y/i adj ep
y/i level believ look reason
updat pacbio regulatori review deal expect close around
updat pull-through novaseq updat
updat average-risk nipt decis acog
dtc mysteri updat expect microarray cours
year given bit paus dtc market-lead recal guid
lsd growth microarray acceler growth ou
greater interest health-focus dtc app
adopt recent launch prime flow cell upgrad hiseq user
novaseq upgrad cycl guid msd increas instrument rev
demonstr confid novaseq upgrad cycl
hiseq user convert play sever year
gm commentari guid gm slightli y/i due mix shift
pop seq larg scale come lower unit econom
growth rate china japan europ outlook
competit commentari relat futur demand high-
throughput sequenc even limit china ou
reason remain bullish see page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
reason remain bullish estim less
penetr full-year revenu basi global tam estim
billion expect remain domin sequenc leader year
come see durabl growth come next sever year result
rise sequenc across mani applic includ liquid biopsi clinic
cancer use liquid biopsi cancer research/pharma use liquid biopsi
nipt inevit inflect pregnant women low-risk birth popul
sequenc project carrier screen microbiom immunom
direct-to-consum test global crispr rare undiagnos genet test
rugd infecti diseas initi blood stream infect clinic use
big pictur updat mean quarterli result updat
guid earlier year estim less human
sequenc less speci sequenc
variant discov genom deciph yet agre
remain begin shift precis medicin
research applic clinic said also think remain begin
term research applic call cite new studi tri
understand link microbiom colon cancer think one
data point among mani come indic much much learn
molecular biolog diseas incid diseas treatment
dtc mysteri nearli direct-to-consum test order alon
use array technolog perform
year ago bit concern would tough comp
clearli mark banner year dtc test said take
cautiou view dtc busi base convers
custom would disclos detail suspicion
and/or ancestri could migrat array exom plu either
provid may take pedal metal kit discount think wrong
investor worri dtc test hit wall expect dtc array
busi reacceler later driven grow interest consum health
applic instanc helix new app mayo clinic among other
like continu contribut growth fairli recent fda-author
health report call guid microarray revenu grow q/q
mid- high-single-digit rang full year expect array revenu grow
low-single-digit rang reflect cautiou view direct-to-consum
new novaseq flow cell prime prime gear toward smaller core
lab prime provid fastest run time lowest run cost longest read
novaseq referenc prime flow cell ideal upgrad user
hiseq indic hudsonalpha institut earli access custom
prime flow cell use prime flow cell immun profil
exom patient talk larg health systems/idn
exom sequenc patient clinic set indic
partnership geising spur convers larg system
integr deliveri network believ greater adopt systemat would
add major upsid sequenc consum growth think take
time play
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
biomed devic servic
biomed devic servic
biomed devic servic
biomed devic servic
